[go: up one dir, main page]

UA96436C2 - Долгосрочное лечение вич-инфекции - Google Patents

Долгосрочное лечение вич-инфекции

Info

Publication number
UA96436C2
UA96436C2 UAA200809750A UAA200809750A UA96436C2 UA 96436 C2 UA96436 C2 UA 96436C2 UA A200809750 A UAA200809750 A UA A200809750A UA A200809750 A UAA200809750 A UA A200809750A UA 96436 C2 UA96436 C2 UA 96436C2
Authority
UA
Ukraine
Prior art keywords
long term
hiv infection
term treatment
formulation
treatment
Prior art date
Application number
UAA200809750A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ливен Эльвир Колетте Баерт
Гуентер Краус
Клустер Гербен Альберт Элеузериус Вант
Original Assignee
Тиботек Фармасьютикелз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36446113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96436(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тиботек Фармасьютикелз Лтд. filed Critical Тиботек Фармасьютикелз Лтд.
Publication of UA96436C2 publication Critical patent/UA96436C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к области медицины и касается применения парентеральной препаративной формы, которая содержит эффективное против вируса количество 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила, его Е-изомерной формы или его Z-изомерной формы; или его фармацевтически приемлемой кислотно-аддитивной соли и носитель, для изготовления лекарственного средства для лечения субъектов, инфицированных ВИЧ, где препаративную форму вводят подкожно или внутримышечно, периодически, с интервалом времени в диапазоне от двух недель до шести месяцев.
UAA200809750A 2006-01-20 2007-01-19 Долгосрочное лечение вич-инфекции UA96436C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100677 2006-01-20

Publications (1)

Publication Number Publication Date
UA96436C2 true UA96436C2 (ru) 2011-11-10

Family

ID=36446113

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200809750A UA96436C2 (ru) 2006-01-20 2007-01-19 Долгосрочное лечение вич-инфекции

Country Status (27)

Country Link
US (4) USRE50189E1 (ru)
EP (1) EP1981506B3 (ru)
JP (2) JP5754005B2 (ru)
KR (2) KR101501475B1 (ru)
CN (2) CN103877091A (ru)
AP (1) AP2936A (ru)
AR (1) AR059097A1 (ru)
AU (1) AU2007206901B2 (ru)
BR (1) BRPI0707179A2 (ru)
CA (1) CA2636436C (ru)
CY (1) CY1114089T1 (ru)
DK (1) DK1981506T6 (ru)
EA (1) EA014914B1 (ru)
ES (1) ES2414982T7 (ru)
HR (1) HRP20130544T4 (ru)
IL (1) IL192132A (ru)
ME (1) ME01617B (ru)
MY (1) MY150717A (ru)
NZ (1) NZ569347A (ru)
PL (1) PL1981506T6 (ru)
PT (1) PT1981506E (ru)
RS (1) RS52821B2 (ru)
SG (1) SG170073A1 (ru)
SI (1) SI1981506T1 (ru)
TW (1) TWI458483B (ru)
UA (1) UA96436C2 (ru)
WO (1) WO2007082922A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
HUE038797T2 (hu) * 2006-06-23 2018-11-28 Janssen Sciences Ireland Uc TMC278 vizes szuszpenziói
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2381961B1 (en) * 2008-12-24 2016-09-14 Janssen Sciences Ireland UC Implantable devices for treating hiv
PL2480220T3 (pl) * 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
MY163383A (en) * 2009-12-21 2017-09-15 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
PH12012501537A1 (en) 2010-01-27 2018-02-07 Viiv Healthcare Co Antiviral therapy
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
US10406098B2 (en) * 2015-11-16 2019-09-10 Evonik Roehm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
US20190163877A1 (en) * 2017-11-27 2019-05-30 International Business Machines Corporation Decision support for effective long-term drug therapy
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (ru) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Водные суспензии субмикронной формы эфиров 9-гидроксирисперидона жирных кислот
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
JP2003509453A (ja) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
HUP0302631A2 (hu) 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
US6568805B1 (en) * 2001-11-26 2003-05-27 Dan L. Dietz Trust Magnetic buckle for eyeglasses
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
JP2006518373A (ja) 2003-02-21 2006-08-10 トリペップ アクチ ボラゲット Ｈｉｖ複製を抑制するためのグリシンアミド誘導体
SI1632232T1 (sl) * 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
ES2526092T3 (es) 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
HUE038797T2 (hu) 2006-06-23 2018-11-28 Janssen Sciences Ireland Uc TMC278 vizes szuszpenziói
ES2437331T3 (es) 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo

Also Published As

Publication number Publication date
AU2007206901A1 (en) 2007-07-26
KR20080085194A (ko) 2008-09-23
EP1981506B3 (en) 2021-06-09
CN103877091A (zh) 2014-06-25
KR101562943B1 (ko) 2015-10-23
IL192132A0 (en) 2009-08-03
ES2414982T3 (es) 2013-07-23
AU2007206901B2 (en) 2013-01-31
JP2009526758A (ja) 2009-07-23
WO2007082922A3 (en) 2007-09-20
CY1114089T1 (el) 2016-07-27
WO2007082922A2 (en) 2007-07-26
KR101501475B1 (ko) 2015-03-19
NZ569347A (en) 2011-07-29
AP2008004535A0 (en) 2008-08-31
AR059097A1 (es) 2008-03-12
EP1981506A2 (en) 2008-10-22
US20110275654A1 (en) 2011-11-10
CN101370504A (zh) 2009-02-18
ME01617B (me) 2014-09-20
DK1981506T6 (da) 2021-06-14
HRP20130544T1 (en) 2013-07-31
JP2013100338A (ja) 2013-05-23
TW200806295A (en) 2008-02-01
HRP20130544T4 (hr) 2021-08-20
IL192132A (en) 2014-05-28
AP2936A (en) 2014-07-31
US20240226099A1 (en) 2024-07-11
HK1125828A1 (en) 2009-08-21
CA2636436A1 (en) 2007-07-26
US20210177843A1 (en) 2021-06-17
EA200870183A1 (ru) 2009-12-30
SG170073A1 (en) 2011-04-29
PL1981506T6 (pl) 2021-07-12
PT1981506E (pt) 2013-06-25
SI1981506T1 (sl) 2013-08-30
PL1981506T3 (pl) 2013-08-30
DK1981506T3 (da) 2013-06-24
USRE50189E1 (en) 2024-10-29
JP5754005B2 (ja) 2015-07-22
ES2414982T7 (es) 2021-11-05
US10953009B2 (en) 2021-03-23
EP1981506B1 (en) 2013-03-27
BRPI0707179A2 (pt) 2011-04-26
JP5836983B2 (ja) 2015-12-24
WO2007082922A8 (en) 2008-01-03
EA014914B1 (ru) 2011-02-28
RS52821B (sr) 2013-10-31
RS52821B2 (sr) 2021-07-30
KR20140141699A (ko) 2014-12-10
MY150717A (en) 2014-02-28
CA2636436C (en) 2014-04-01
TWI458483B (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
UA96436C2 (ru) Долгосрочное лечение вич-инфекции
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
ZA202002139B (en) Combination pharmaceutical agents as rsv inhibitors
NZ627824A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
PH12014500386A1 (en) Combination treatment for hepatitis c
NZ595313A (en) The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
TW200518758A (en) HIV replication inhibiting purine derivatives
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
MX2009010642A (es) Antibioticos de oxazolidinona.
MX2010008921A (es) Derivados de oxazolidinona.
WO2005089738A3 (en) Use and administration of bacterial efflux pump inhibitors
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
NZ600912A (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
UA90124C2 (ru) Способ профилактики вич-инфекции с помощью тмс278
WO2012024363A3 (en) Compounds and methods for the treatment or prevention of flaviviridae viral infections
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
GB0229022D0 (en) Organic Compounds
WO2011036159A3 (en) Treatment and prevention of hiv infection
MD3446F1 (en) Method of HIV infection treatment